409 related articles for article (PubMed ID: 12642304)
21. High-dose intravenous steroid pulse therapy in ocular involvement of Behcet's disease: a pilot double-blind controlled study.
Mohammadi M; Shahram F; Shams H; Akhlaghi M; Ashofteh F; Davatchi F
Int J Rheum Dis; 2017 Sep; 20(9):1269-1276. PubMed ID: 28524639
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of interferon-alpha in the treatment of corticodependent uveitis of paediatric Behcet's disease.
Guillaume-Czitrom S; Berger C; Pajot C; Bodaghi B; Wechsler B; Kone-Paut I
Rheumatology (Oxford); 2007 Oct; 46(10):1570-3. PubMed ID: 17702770
[TBL] [Abstract][Full Text] [Related]
23. High dose methotrexate for ocular lesions of Behçet's disease. Preliminary short-term results.
Davatchi F; Shahram F; Chams H; Jamshidi AR; Nadji A; Chams C; Akbarian M; Gharibdoost F
Adv Exp Med Biol; 2003; 528():579-84. PubMed ID: 12918769
[No Abstract] [Full Text] [Related]
24. Long-term remission after cessation of interferon-α treatment in patients with severe uveitis due to Behçet's disease.
Deuter CM; Zierhut M; Möhle A; Vonthein R; Stöbiger N; Kötter I
Arthritis Rheum; 2010 Sep; 62(9):2796-805. PubMed ID: 20518075
[TBL] [Abstract][Full Text] [Related]
25. Ocular Manifestations and Visual Outcomes of Behçet's Uveitis in a Thai population.
Pathanapitoon K; Kunavisarut P; Saravuttikul FA; Rothova A
Ocul Immunol Inflamm; 2019; 27(1):2-6. PubMed ID: 29020486
[TBL] [Abstract][Full Text] [Related]
26. Long-term efficacy and safety of interferon α-2a therapy in severe refractory ophthalmic Behcet's disease.
Kavandi H; Khabbazi A; Kolahi S; Hajialilo M; Shayan FK; Oliaei M
Clin Rheumatol; 2016 Nov; 35(11):2765-2769. PubMed ID: 27234230
[TBL] [Abstract][Full Text] [Related]
27. Vitrectomy and trabeculectomy combined with interferon alpha treatment in Adamantiades-Behçet's disease: a case report.
Krause L; Hoffmann F; Zouboulis CC; Foerster MH
Graefes Arch Clin Exp Ophthalmol; 2003 Oct; 241(10):871-4. PubMed ID: 13680252
[TBL] [Abstract][Full Text] [Related]
28. Rituximab in intractable ocular lesions of Behcet's disease; randomized single-blind control study (pilot study).
Davatchi F; Shams H; Rezaipoor M; Sadeghi-Abdollahi B; Shahram F; Nadji A; Chams-Davatchi C; Akhlaghi M; Faezi T; Naderi N
Int J Rheum Dis; 2010 Aug; 13(3):246-52. PubMed ID: 20704622
[TBL] [Abstract][Full Text] [Related]
29. [Efficacy of TNF-alpha antagonist and other immunomodulators in the treatment of patients with ophthalmologic manifestations of Behcet's disease and HLA B51 positive vasculitis].
Zlatanović G; Jovanović S; Veselinović D; Zivković M
Vojnosanit Pregl; 2012 Feb; 69(2):168-74. PubMed ID: 22500372
[TBL] [Abstract][Full Text] [Related]
30. Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease: an open-label pilot study.
Gül A; Tugal-Tutkun I; Dinarello CA; Reznikov L; Esen BA; Mirza A; Scannon P; Solinger A
Ann Rheum Dis; 2012 Apr; 71(4):563-6. PubMed ID: 22084392
[TBL] [Abstract][Full Text] [Related]
31. [Ocular manifestations in Behçet's disease].
Desbois AC; Terrada C; Cacoub P; Bodaghi B; Saadoun D
Rev Med Interne; 2018 Sep; 39(9):738-745. PubMed ID: 29625716
[TBL] [Abstract][Full Text] [Related]
32. Interferon alfa combined with azathioprine for the uveitis of Behçet's disease: an open study.
Hamuryudan V; Ozyazgan Y; Fresko Y; Mat C; Yurdakul S; Yazici H
Isr Med Assoc J; 2002 Nov; 4(11 Suppl):928-30. PubMed ID: 12455182
[TBL] [Abstract][Full Text] [Related]
33. Pattern of uveitis in Behçet's disease in a referral center in Tunisia, North Africa.
Khairallah M; Attia S; Yahia SB; Jenzeri S; Ghrissi R; Jelliti B; Zaouali S; Messaoud R
Int Ophthalmol; 2009 Jun; 29(3):135-41. PubMed ID: 18365145
[TBL] [Abstract][Full Text] [Related]
34. Eye and Behçet's disease.
Ksiaa I; Abroug N; Kechida M; Zina S; Jelliti B; Khochtali S; Attia S; Khairallah M
J Fr Ophtalmol; 2019 Apr; 42(4):e133-e146. PubMed ID: 30850197
[TBL] [Abstract][Full Text] [Related]
35. Interferon alpha for ocular Behçet's disease.
Pivetti-Pezzi P; Accorinti M; Pirraglia MP; Priori R; Valesini G
Acta Ophthalmol Scand; 1997 Dec; 75(6):720-2. PubMed ID: 9527339
[TBL] [Abstract][Full Text] [Related]
36. Gender influence on ocular manifestations and their outcome in Behcet's Disease. A long-term follow-up of up to 20 years.
Davatchi F; Shahram F; Shams H; Nadji A; Chams-Davatchi C; Akhlaghi M; Faezi ST; Ashofteh F; Sadeghi-Abdollahi B
Clin Rheumatol; 2011 Apr; 30(4):541-7. PubMed ID: 20857156
[TBL] [Abstract][Full Text] [Related]
37. Interferon alfa-2a in the treatment of Behçet's disease.
Azizlerli G; Sarica R; Köse A; Ovül C; Kavala M; Kayabali M; Erkan F; Kural Z
Dermatology; 1996; 192(3):239-41. PubMed ID: 8726638
[TBL] [Abstract][Full Text] [Related]
38. Interferon alfa-2a in the treatment of ocular Adamantiades-Behçet's disease.
Krause L; Turnbull JR; Torun N; Pleyer U; Zouboulis CC; Foerster MH
Adv Exp Med Biol; 2003; 528():511-9. PubMed ID: 12918754
[No Abstract] [Full Text] [Related]
39. Long-Term Efficacy of Pegylated Interferon Alpha-2b in Behçet's Uveitis: A Small Case Series.
Celiker H; Kazokoglu H; Direskeneli H
Ocul Immunol Inflamm; 2019; 27(1):15-22. PubMed ID: 28700247
[TBL] [Abstract][Full Text] [Related]
40. Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behçet disease.
Gueudry J; Wechsler B; Terrada C; Gendron G; Cassoux N; Fardeau C; Lehoang P; Piette JC; Bodaghi B
Am J Ophthalmol; 2008 Dec; 146(6):837-44.e1. PubMed ID: 19027420
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
